The text starts here.

News Release

FOR IMMEDIATE RELEASE
March 16, 2000

PARIET, A PROTON PUMP INHIBITOR, LICENSED TO JANSSEN FOR MARKETING IN FRANCE

PARIET, A PROTON PUMP INHIBITOR, LICENSED TO JANSSEN FOR MARKETING IN FRANCE


Tokyo (March 16, 2000) - Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) today announced that Janssen Pharmaceutica (Head Office: Beerse, Belgium) and Eisai have reached an exclusive agreement for the marketing of PARIET (generic name: rabeprazole sodium), a proton pump inhibitor, in France by Janssen-Cilag. The product was launched in France on March 15, 2000.


Eisai first launched PARIET in Japan in December 1997. Subsequently, PARIET was cleared for marketing in all 15 EU countries through the Mutual Recognition Procedure in September 1998, and sales began in the United Kingdom in September 1998, and in Germany in December 1998. In addition, in August 1999, sales of the product, (U.S. tradename: ACIPHEX) began in the United States. Eisai Co., Ltd. and Janssen Pharmaceutica currently copromote PARIET in the United Kingdom, Germany, and ACIPHEX in the United States. In most other countries in the world excluding Japan and Asia, Janssen-Cilag has marketing rights for PARIET.


Currently the product has been launched in 20 countries and approved for marketing in an additional 25 countries.


PARIET is classified as a proton pump inhibitor and demonstrates strong proton pump inhibition at the final stage of acid secretion by blocking the function of the enzyme responsible for stomach acid production.


PARIET is also approved in all EU countries for the treatment of symptomatic erosive or ulcerative gastro-oesophageal reflux disease (GORD), GORD maintenance, active duodenal and active benign gastric ulcers.